PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31324713-1 2020 In preclinical trials, the recently developed tracer 2-methoxy-18F-DCFPyL (18F-JK-prostate-specific membrane antigen [PSMA]-7) has shown favorable properties regarding clinical performance and radiochemical accessibility. Fluorine-18 62-66 folate hydrolase 1 Homo sapiens 75-116 33669095-2 2021 [18F]PSMA-1007, a radiopharmaceutical labeled with fluorine-18, has excellent properties for the detection of prostate cancer. Fluorine-18 51-62 folate hydrolase 1 Homo sapiens 5-9 32789599-3 2021 Besides the frequently used 68gallium-labelled PSMA tracers, 18fluorine-labelled PSMA tracers are available. Fluorine-18 61-71 folate hydrolase 1 Homo sapiens 81-85 31000583-3 2019 The aim of this study was to perform a full pharmacokinetic analysis of 2-(3-(1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid (18F-DCFPyL), a second-generation 18F-labeled PSMA ligand. Fluorine-18 94-97 folate hydrolase 1 Homo sapiens 213-217 30843003-55 2019 Fluorine-18-PSMA-1007 has been recently used by us in the Nuclear Medicine Department of "Evangelismos" general hospital of Athens and our experience so far showed favorable results, with high image resolution acquisitions and lesions which showed PSMA avidity. Fluorine-18 0-11 folate hydrolase 1 Homo sapiens 12-16 31230088-2 2019 Alternatively, fluorine-18 (18F)-labelled PSMA tracers are available, such as 18F-DCFPyL, which offer enhanced image quality and therefore potentially increased detection of small metastases. Fluorine-18 15-26 folate hydrolase 1 Homo sapiens 42-46 30843003-55 2019 Fluorine-18-PSMA-1007 has been recently used by us in the Nuclear Medicine Department of "Evangelismos" general hospital of Athens and our experience so far showed favorable results, with high image resolution acquisitions and lesions which showed PSMA avidity. Fluorine-18 0-11 folate hydrolase 1 Homo sapiens 248-252 29939893-4 2018 RECENT FINDINGS: Development in small PSMA-targeted molecules labeled with gallium-68 and fluorine-18 show promising results for primary staging and detection of disease at biochemical recurrence using PET/computed tomography (PET/CT). Fluorine-18 90-101 folate hydrolase 1 Homo sapiens 38-42 30281701-4 2018 Different PSMA ligands have been used for this purpose including 68gallium and 18fluorine-labeled PET probes, which have particular features including spatial resolution, imaging quality and tracer biodistribution. Fluorine-18 79-89 folate hydrolase 1 Homo sapiens 10-14 27847991-3 2017 We aimed to develop high-affinity PSMA inhibitors labeled with fluorine-18 as alternative tracers for prostate cancer. Fluorine-18 63-74 folate hydrolase 1 Homo sapiens 34-38 29503861-3 2018 Previous methods to synthetize 18F-labeled PSMA ligands with complexes [18F]AlF2+ have been achieved. Fluorine-18 31-34 folate hydrolase 1 Homo sapiens 43-47 28950199-5 2017 Here, we describe a simple synthesis and validation of a fluorine-18 labeled Glu-urea-Lys(Ahx)-HBED-CC ([Al18F]PSMA-11) for nuclear medicine applications. Fluorine-18 57-68 folate hydrolase 1 Homo sapiens 111-115 28953234-2 2017 In this connection, we recently developed the fluorine-18-labelled PSMA-ligand [18F]PSMA-1007 as the next generation radiofluorinated Glu-ureido PSMA inhibitor after [18F]DCFPyL and [18F]DCFBC. Fluorine-18 46-57 folate hydrolase 1 Homo sapiens 67-71 28953234-2 2017 In this connection, we recently developed the fluorine-18-labelled PSMA-ligand [18F]PSMA-1007 as the next generation radiofluorinated Glu-ureido PSMA inhibitor after [18F]DCFPyL and [18F]DCFBC. Fluorine-18 46-57 folate hydrolase 1 Homo sapiens 84-88 28953234-2 2017 In this connection, we recently developed the fluorine-18-labelled PSMA-ligand [18F]PSMA-1007 as the next generation radiofluorinated Glu-ureido PSMA inhibitor after [18F]DCFPyL and [18F]DCFBC. Fluorine-18 46-57 folate hydrolase 1 Homo sapiens 84-88 26169882-11 2015 The data acquired in this manuscript confirmed that our new generation of [(18)F]-labeled PSMA inhibitor exhibited promising in vivo performance as a PET imaging agent for PCa and is well-positioned for subsequent clinical trials. Fluorine-18 74-81 folate hydrolase 1 Homo sapiens 90-94 24615708-9 2014 Using a fluorine-18 labeled PSMA targeting tracer, we found that these highly negatively charged molecules exhibit rapid renal excretion with minimal non-specific binding. Fluorine-18 8-19 folate hydrolase 1 Homo sapiens 28-32 25896814-2 2015 Here we present initial safety, biodistribution, and radiation dosimetry results with [(18)F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate cancer. Fluorine-18 121-132 folate hydrolase 1 Homo sapiens 156-160 34747721-1 2021 This paper presents a meta-analysis regarding the detection rate (DR) of fluorine-18 (18F)-labeled prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) in the management of patients with prostate cancer (PCa). Fluorine-18 73-84 folate hydrolase 1 Homo sapiens 184-188 35560134-2 2022 18F-PSMA-7Q is a novel 18F-labeled PSMA-ligand PET tracer designed and synthesized by our team. Fluorine-18 0-4 folate hydrolase 1 Homo sapiens 35-39 35560134-2 2022 18F-PSMA-7Q is a novel 18F-labeled PSMA-ligand PET tracer designed and synthesized by our team. Fluorine-18 23-26 folate hydrolase 1 Homo sapiens 4-8 35560134-2 2022 18F-PSMA-7Q is a novel 18F-labeled PSMA-ligand PET tracer designed and synthesized by our team. Fluorine-18 23-26 folate hydrolase 1 Homo sapiens 35-39